Literature DB >> 22424252

Nonparticipation in a population-based trial to increase colorectal cancer screening.

Beverly B Green1, Andy Bogart, Jessica Chubak, Sally W Vernon, Leo S Morales, Richard T Meenan, Sharon S Laing, Sharon Fuller, Cynthia Ko, Ching-Yun Wang.   

Abstract

BACKGROUND: Many trials have tested different strategies to increase colorectal cancer (CRC) screening. Few describe whether participants are representative of the population from which they are recruited.
PURPOSE: To determine risk factors related to nonparticipation among patients enrolled in an integrated health plan and not up to date for CRC testing, in a trial to increase screening rates.
METHODS: Between July 2008 and October 2009, a total of 15,000 adults aged 50-74 years from 21 clinics in Washington State who were due for CRC screening were contacted. Nonparticipants were defined as English-speaking patients who did not engage in the call or refused participation while still potentially eligible. Log-binomial regression models were used to estimate the relative risk of nonparticipation. Analyses were completed between October 2010 and June 2011.
RESULTS: Patients who were nonwhite, had less education, used tobacco, had less continuity of care, and had lower rates of preventive care and cancer screening were more likely to be nonparticipants. Patients reporting never having received any type of CRC testing or screening were also more likely not to participate (62% of nonparticipants vs 46% of participants; adjusted RR=1.58, 95% CI=1.47, 1.70). Reasons for refusal included costs, risks of procedures, and not wanting their medical records reviewed.
CONCLUSIONS: Patients eligible for but not participating in the trial were more likely to be from minority socioeconomic and racial groups and had behaviors that can negatively affect cancer outcomes. Additional efforts are needed to recruit patients who need CRC screening the most. TRIAL REGISTRATION: This trial is registered at clinicaltrials.gov NCT 00697047. Copyright Â
© 2012 American Journal of Preventive Medicine. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22424252      PMCID: PMC3549634          DOI: 10.1016/j.amepre.2011.11.014

Source DB:  PubMed          Journal:  Am J Prev Med        ISSN: 0749-3797            Impact factor:   5.043


  28 in total

1.  Evaluating the impact of health promotion programs: using the RE-AIM framework to form summary measures for decision making involving complex issues.

Authors:  Russell E Glasgow; Lisa M Klesges; David A Dzewaltowski; Paul A Estabrooks; Thomas M Vogt
Journal:  Health Educ Res       Date:  2006-08-31

Review 2.  Screening for colorectal cancer using the faecal occult blood test, Hemoccult.

Authors:  P Hewitson; P Glasziou; L Irwig; B Towler; E Watson
Journal:  Cochrane Database Syst Rev       Date:  2007-01-24

3.  The HIPAA authorization form and effects on survey response rates, nonresponse bias, and data quality: a randomized community study.

Authors:  Timothy J Beebe; Nicholas J Talley; Michael Camilleri; Sarah M Jenkins; Kari J Anderson; G Richard Locke
Journal:  Med Care       Date:  2007-10       Impact factor: 2.983

4.  Generalizability of the results of randomized trials.

Authors:  Noel S Weiss; Thomas D Koepsell; Bruce M Psaty
Journal:  Arch Intern Med       Date:  2008-01-28

Review 5.  Barriers to recruiting underrepresented populations to cancer clinical trials: a systematic review.

Authors:  Jean G Ford; Mollie W Howerton; Gabriel Y Lai; Tiffany L Gary; Shari Bolen; M Chris Gibbons; Jon Tilburt; Charles Baffi; Teerath Peter Tanpitukpongse; Renee F Wilson; Neil R Powe; Eric B Bass
Journal:  Cancer       Date:  2008-01-15       Impact factor: 6.860

6.  Using RE-AIM metrics to evaluate diabetes self-management support interventions.

Authors:  Russell E Glasgow; Candace C Nelson; Lisa A Strycker; Diane K King
Journal:  Am J Prev Med       Date:  2006-01       Impact factor: 5.043

Review 7.  Randomisation to protect against selection bias in healthcare trials.

Authors:  R Kunz; G Vist; A D Oxman
Journal:  Cochrane Database Syst Rev       Date:  2007-04-18

8.  Promoting regular mammography screening I. A systematic assessment of validity in a randomized trial.

Authors:  Deborah J del Junco; Sally W Vernon; Sharon P Coan; Jasmin A Tiro; Lori A Bastian; Lara S Savas; Catherine A Perz; David R Lairson; Wen Chan; Cynthia Warrick; Amy McQueen; William Rakowski
Journal:  J Natl Cancer Inst       Date:  2008-02-26       Impact factor: 13.506

9.  Recruitment in the prostate, lung, colorectal, and ovarian (PLCO) cancer screening trial: the first phase of recruitment at Henry Ford Health System.

Authors:  Lois E Lamerato; Pamela M Marcus; Gordon Jacobsen; Christine Cole Johnson
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-04       Impact factor: 4.254

Review 10.  Are racial and ethnic minorities less willing to participate in health research?

Authors:  David Wendler; Raynard Kington; Jennifer Madans; Gretchen Van Wye; Heidi Christ-Schmidt; Laura A Pratt; Otis W Brawley; Cary P Gross; Ezekiel Emanuel
Journal:  PLoS Med       Date:  2005-12-06       Impact factor: 11.069

View more
  18 in total

1.  Uptake and positive predictive value of fecal occult blood tests: A randomized controlled trial.

Authors:  Jessica Chubak; Andy Bogart; Sharon Fuller; Sharon S Laing; Beverly B Green
Journal:  Prev Med       Date:  2013-09-09       Impact factor: 4.018

2.  An economic evaluation of colorectal cancer screening in primary care practice.

Authors:  Richard T Meenan; Melissa L Anderson; Jessica Chubak; Sally W Vernon; Sharon Fuller; Ching-Yun Wang; Beverly B Green
Journal:  Am J Prev Med       Date:  2015-06       Impact factor: 5.043

3.  Impact of continued mailed fecal tests in the patient-centered medical home: Year 3 of the Systems of Support to Increase Colon Cancer Screening and Follow-Up randomized trial.

Authors:  Beverly B Green; Melissa L Anderson; Jessica Chubak; Sharon Fuller; Richard T Meenan; Sally W Vernon
Journal:  Cancer       Date:  2015-10-21       Impact factor: 6.860

4.  A centralized mailed program with stepped increases of support increases time in compliance with colorectal cancer screening guidelines over 5 years: A randomized trial.

Authors:  Beverly B Green; Melissa L Anderson; Andrea J Cook; Jessica Chubak; Sharon Fuller; Richard T Meenan; Sally W Vernon
Journal:  Cancer       Date:  2017-07-28       Impact factor: 6.860

5.  Time to fecal immunochemical test completion for colorectal cancer screening.

Authors:  Cameron B Haas; Amanda I Phipps; Anjum Hajat; Jessica Chubak; Karen J Wernli
Journal:  Am J Manag Care       Date:  2019-04       Impact factor: 2.229

6.  Longitudinal predictors of colorectal cancer screening among participants in a randomized controlled trial.

Authors:  Caitlin C Murphy; Sally W Vernon; Nicole M Haddock; Melissa L Anderson; Jessica Chubak; Beverly B Green
Journal:  Prev Med       Date:  2014-06-15       Impact factor: 4.018

7.  Colorectal Cancer Screening Rates Increased after Exposure to the Patient-Centered Medical Home (PCMH).

Authors:  Beverly B Green; Melissa L Anderson; Jessica Chubak; Laura Mae Baldwin; Leah Tuzzio; Sheryl Catz; Alison Cole; Sally W Vernon
Journal:  J Am Board Fam Med       Date:  2016 Mar-Apr       Impact factor: 2.657

8.  Patient trust in physician influences colorectal cancer screening in low-income patients.

Authors:  Shivani Gupta; Alison T Brenner; Neda Ratanawongsa; John M Inadomi
Journal:  Am J Prev Med       Date:  2014-07-29       Impact factor: 5.043

9.  Integrating men's health and masculinity theories to explain colorectal cancer screening behavior.

Authors:  Shannon M Christy; Catherine E Mosher; Susan M Rawl
Journal:  Am J Mens Health       Date:  2013-06-27

10.  Attitudes toward molecular testing for personalized cancer therapy.

Authors:  Rafeek A Yusuf; Deevakar Rogith; Shelly R A Hovick; Susan K Peterson; Allison M Burton-Chase; Bryan M Fellman; Yisheng Li; Carolyn McKinney; Elmer V Bernstam; Funda Meric-Bernstam
Journal:  Cancer       Date:  2014-09-10       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.